Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Kolltan Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Kolltan Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Kolltan Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Kolltan Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Kolltan Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Kolltan Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Kolltan Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Kolltan Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Kolltan Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kolltan Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Kolltan Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Kolltan Pharmaceuticals, Inc. Snapshot 5 Kolltan Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Kolltan Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Kolltan Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Kolltan Pharmaceuticals, Inc. - Pipeline Products Glance 11 Kolltan Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 Kolltan Pharmaceuticals, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Kolltan Pharmaceuticals, Inc. - Drug Profiles 14 KTN-3379 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 KIT-ADC 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 KTN-0158 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Monoclonal Antibody to Inhibit ALK for Cancer 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Monoclonal Antibody to Inhibit Axl for Cancer, Inflammation and Infection 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Monoclonal Antibody to Inhibit c-MET for Cancer 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibody to Inhibit FGFR4 for Cancer 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Monoclonal Antibody to Inhibit MERTK for Cancer, Inflammation and Infection 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Monoclonal Antibody to Inhibit RON for Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Kolltan Pharmaceuticals, Inc. - Pipeline Analysis 24 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Target 24 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 25 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 26 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 27 Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates 28 Kolltan Pharmaceuticals, Inc. - Locations And Subsidiaries 30 Head Office 30 Other Locations & Subsidiaries 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables Kolltan Pharmaceuticals, Inc., Key Information 5 Kolltan Pharmaceuticals, Inc., Key Facts 5 Kolltan Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Kolltan Pharmaceuticals, Inc. - Phase I, 2014 11 Kolltan Pharmaceuticals, Inc. - Preclinical, 2014 12 Kolltan Pharmaceuticals, Inc. - Discovery, 2014 13 Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2014 24 Kolltan Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 25 Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 26 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 27 Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 28 Kolltan Pharmaceuticals, Inc., Subsidiaries 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.